DK0580860T4
(da)
*
|
1991-04-16 |
2005-03-21 |
Nippon Shinyaku Co Ltd |
Fremgangsmåde til fremstilling af en fast dispersion
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP0729748B1
(de)
*
|
1993-11-18 |
2003-02-26 |
Nippon Shinyaku Company, Limited |
Verfahren zur herstellung stabiler arzneimittel
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
FR2729077A1
(fr)
*
|
1995-01-05 |
1996-07-12 |
Oreal |
Composition cosmetique sous forme d'une pate souple et procede de preparation
|
SE9700135D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
EP0901786B1
(de)
*
|
1997-08-11 |
2007-06-13 |
Pfizer Products Inc. |
Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6106862A
(en)
|
1998-08-13 |
2000-08-22 |
Andrx Corporation |
Once daily analgesic tablet
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
ITMI991316A1
(it)
*
|
1999-06-14 |
2000-12-14 |
Cip Ninety Two 92 S A |
Composizioni farmaceutiche orali a rilascio modificato di mesalazina
|
NZ529928A
(en)
|
1999-10-29 |
2005-10-28 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
SE0003125D0
(sv)
*
|
2000-09-05 |
2000-09-05 |
Astrazeneca Ab |
Modified polymers
|
JP2004512354A
(ja)
|
2000-10-30 |
2004-04-22 |
ユーロ−セルティーク,エス.エイ. |
ヒドロコドン放出制御製剤
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
US7052706B2
(en)
*
|
2001-06-08 |
2006-05-30 |
Nostrum Pharmaceuticals, Inc. |
Control release formulation containing a hydrophobic material as the sustained release agent
|
US7022342B2
(en)
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US6986901B2
(en)
*
|
2002-07-15 |
2006-01-17 |
Warner-Lambert Company Llc |
Gastrointestinal compositions
|
CA2491797A1
(en)
*
|
2002-07-10 |
2004-01-22 |
Warner-Lambert Company Llc |
Gastrointestinal compositions
|
US20040010035A1
(en)
*
|
2002-07-15 |
2004-01-15 |
Ciociola Arthur A. |
Gastrointestinal compositions
|
KR20040016202A
(ko)
*
|
2002-08-16 |
2004-02-21 |
주식회사 제이알팜 |
쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
|
JP4808612B2
(ja)
*
|
2003-04-25 |
2011-11-02 |
田辺三菱製薬株式会社 |
アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
|
US7364755B2
(en)
*
|
2003-07-07 |
2008-04-29 |
Synthon Ip Inc. |
Modified calcium phosphate excipient
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
GB0403098D0
(en)
|
2004-02-12 |
2004-03-17 |
Euro Celtique Sa |
Extrusion
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
JP2008539240A
(ja)
*
|
2005-04-25 |
2008-11-13 |
テバ ファーマシュ−ティカルズ ユーエスエー, インコーポレイテッド |
持続放出性処方物
|
US8153162B2
(en)
|
2005-09-27 |
2012-04-10 |
Tissuetech, Inc. |
Purified amniotic membrane compositions and methods of use
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
AP3071A
(en)
|
2005-11-28 |
2014-12-31 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the makingand use thereof
|
US20090047357A1
(en)
|
2005-12-22 |
2009-02-19 |
Otsuka Pharmaceutical Co., Ltd. |
Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
|
GB0600913D0
(en)
*
|
2006-01-17 |
2006-02-22 |
Syngenta Ltd |
Improvements in or relating to organic compounds
|
US20070185065A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Vikramjit Chhokar |
Combination therapy for coronary artery disease
|
US20070243237A1
(en)
*
|
2006-04-14 |
2007-10-18 |
Mazen Khaled |
Antimicrobial thin film coating and method of forming the same
|
US20080090897A1
(en)
|
2006-08-11 |
2008-04-17 |
The Johns Hopkins University |
Compositions and methods for neuroprotectin
|
DK2529622T3
(en)
|
2006-09-22 |
2018-05-07 |
Pharmacyclics Llc |
INHIBITORS OF BRUTON-TYROSINKINASE
|
CA2699157A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
RU2472791C2
(ru)
|
2008-08-27 |
2013-01-20 |
КалсиМедика Инк. |
Соединения, модулирующие внутриклеточный кальций
|
DK2421901T3
(en)
|
2009-04-24 |
2016-01-11 |
Tissue Tech Inc |
Compositions comprising HC-HA complex, and methods of use thereof
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
WO2011090724A2
(en)
*
|
2009-12-29 |
2011-07-28 |
Impax Laboratories, Inc. |
Gastroretentive solid oral dosage forms with lipid-based low-density excipient
|
US20130030237A1
(en)
|
2010-04-15 |
2013-01-31 |
Charles Theuer |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
JP2013525448A
(ja)
|
2010-04-27 |
2013-06-20 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
BR112012030625A2
(pt)
|
2010-06-03 |
2017-06-27 |
Pharmacyclics Inc |
uso de inibidores de tirosina quinase de bruton (btk)
|
WO2012027710A2
(en)
|
2010-08-27 |
2012-03-01 |
Calcimedica Inc. |
Compounds that modulate intracellular calcium
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
EP2717888B1
(de)
|
2011-06-10 |
2020-09-09 |
Tissuetech, Inc. |
Verfahren zur verarbeitung fötaler gewebesubstrate
|
NZ621221A
(en)
|
2011-09-13 |
2016-07-29 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
US9364549B2
(en)
*
|
2011-11-30 |
2016-06-14 |
Andreas Voigt |
Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
RS60569B1
(sr)
|
2012-01-06 |
2020-08-31 |
Lundbeck La Jolla Research Center Inc |
Jedinjenja karbamata i postupci njihovog pravljenja i upotrebe
|
CA3015208C
(en)
|
2012-06-04 |
2024-01-02 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック,インク. |
Hc−ha/ptx3複合体を含む組成物およびその使用方法
|
DK2900674T3
(en)
|
2012-09-28 |
2017-07-03 |
Univ Washington Through Its Center For Commercialization |
RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
MX2016007111A
(es)
|
2013-12-05 |
2016-08-11 |
Pharmacyclics Llc |
Inhibidores de tirosina quinasa de bruton.
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
AU2016215023B2
(en)
|
2015-02-06 |
2019-12-19 |
Fred Hutchinson Cancer Center |
Compounds and methods for preventing or treating sensory hair cell death
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
JP2018510138A
(ja)
|
2015-02-27 |
2018-04-12 |
カーテナ ファーマシューティカルズ,インク. |
Olig2活性の阻害
|
CA3177990A1
(en)
|
2015-03-03 |
2016-09-09 |
Pharmacyclics Llc |
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
WO2016183097A1
(en)
|
2015-05-11 |
2016-11-17 |
Abide Therapeutics, Inc. |
Methods of treating inflammation or neuropathic pain
|
CA2984443A1
(en)
|
2015-05-20 |
2016-11-24 |
Tissuetech, Inc. |
Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
|
CA2996177A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
CA3008289C
(en)
|
2015-12-16 |
2023-10-31 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced sh2 protein in nk cells
|
AU2017208473B2
(en)
|
2016-01-19 |
2022-04-21 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a BTK inhibitor
|
CA3008338A1
(en)
|
2016-01-19 |
2017-07-27 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a btk inhibitor
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
AU2017246334C1
(en)
|
2016-04-04 |
2022-11-17 |
Sinopia Biosciences, Inc. |
Treating extrapyramidal syndrome using Trapidil
|
EP3463576A4
(de)
|
2016-05-25 |
2020-01-15 |
Concentric Analgesics, Inc. |
Prodrugs von phenolischen trpv1-agonisten in kombination mit lokalanästhetika und vasokonstriktoren für verbesserte lokalanästhesie
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
PT3484862T
(pt)
|
2016-07-18 |
2021-11-17 |
Arthrosi Therapeutics Inc |
Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
|
EP3504195A4
(de)
|
2016-08-26 |
2020-01-29 |
Curtana Pharmaceuticals, Inc. |
Hemmung der olig2-aktivität
|
CA3043610A1
(en)
|
2016-11-16 |
2018-05-24 |
Abide Therapeutics, Inc. |
Crystalline forms of a magl inhibitor
|
MA46867A
(fr)
|
2016-11-16 |
2019-09-25 |
Abide Therapeutics Inc |
Formulations pharmaceutiques
|
JP7397487B2
(ja)
|
2017-09-01 |
2023-12-13 |
ユニヴァーシティ オブ ワシントン |
感覚有毛細胞死を予防または処置するための化合物の結晶形態
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
US10717712B2
(en)
|
2018-07-27 |
2020-07-21 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic TRPV1 agonists
|
AU2019417833A1
(en)
|
2018-12-31 |
2021-06-24 |
Biomea Fusion, Inc. |
Irreversible inhibitors of menin-MLL interaction
|
CA3133093A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics, Inc. |
Nicorandil derivatives
|
EP4139288A1
(de)
|
2020-04-21 |
2023-03-01 |
H. Lundbeck A/S |
Synthese eines monoacylglycerol-lipasehemmers
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
CA3218884A1
(en)
|
2021-05-11 |
2022-11-17 |
David Nutt |
Therapeutic aminoindane compounds and compositions
|
WO2022256720A2
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
AU2022331496A1
(en)
|
2021-08-20 |
2024-02-29 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
AU2022426699A1
(en)
|
2021-12-30 |
2024-07-11 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of flt3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|